Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations

Cancer Chemotherapy and Pharmacology

Volumn 34, Issue 1 Supplement, 1994, Pages

  Stewart, Clinton F ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Etoposide; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CISPLATIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; NITROSOUREA DERIVATIVE; PODOPHYLLOTOXIN DERIVATIVE; STREPTOZOCIN;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG DISPOSITION; DRUG METABOLISM; DRUG PROTEIN BINDING; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MALIGNANT NEOPLASTIC DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL;

ETOPOSIDE; HUMAN; INTESTINAL ABSORPTION; KIDNEY; LIVER; NEOPLASMS; RENAL DIALYSIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028086015     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00684868     Document Type: Article

References (50)

1. Etoposide pharmacokinetics in patients with normal and abnormal organ function
2. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer
3. Guide to drug dosage in renal failure
4. Protein binding and kinetics of drugs in liver diseases
5. Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma
6. Influence of liver function on drug disposition
7. Comparison of the biologic activity of VP-16-213 given IV and orally in capsules or drink ampules
8. Evaluation of aminoglycoside disposition in patients previously treated with cisplatin
9. Metabolic studies of a podophyllotoxin derivative (VP16) in the isolated perfused liver
10. The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate
11. Pharmacokinetics of VP16-213 given by different administration methods
12. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function
13. Pharmacokinetics of teniposide (VM26) and etoposide in children with cancer
14. Etoposide: an update
15. Factors affecting in vitro protein binding of etoposide in humans
16. Interspecies differences in in vitro etoposide plasma protein binding
17. Etoposide: seeking the best dose and schedule
18. Pharmacokinetics of high-dose etoposide (VP-16-213) adminstered to cancer patients
19. Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit
20. Metabolism and excretion of etoposide in isolated, perfused rat liver model
21. Etoposide kinetics in patients with obstructive jaundice
22. Bioavailability of low-dose oral etoposide
23. Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient
24. Pharmacokinetics of high dose etoposide (VP16-213)
25. Renal function and etoposide pharmacokinetics: is dose modification necessary?
26. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation
27. Influence of renal function and dialysis on drug disposition
28. Inadequacy of predicted creatinine clearance as guide to chemotherapy
29. Estimating creatinine clearance in patients with cancer
30. Modeling interpatient pharmacodynamic variability of etoposide
31. Clinical pharmacodynamics of continuous-infusion etoposide
32. Patients at risk of chemotherapy-associated toxicity in small cell lung cancer
33. Phase I pharmacokinetic study of intraperitoneal etoposide
34. Drug monitoring of etoposide (VP 16-213): correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide
35. Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters and clinical conditions
36. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability
37. Pharmacodynamics in cancer therapy
38. Human cytochrome P450 metabolism of teniposide and etoposide
39. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial
40. Disposition of total and unbound etoposide following high-dose therapy
41. Pharmacokinetics of etoposide (VP-16) in children and adolescents with refractory solid tumors
42. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer
43. Altered protein binding of etoposide in patients with cancer
44. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction
45. Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients
46. Relation of systemic exposure to unbound etoposide and hematologic toxicity
47. Chemotherapy drugs
48. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide
49. Estimation of creatinine clearance in patients with gynecologic cancer
50. In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy